Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMVXUR0)

Drug Name	Magrolimab DMVXUR0
Synonyms	GS-4721
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Myelodysplastic syndrome	DISYHNUI	2A37	Phase 3	[1]
Acute myeloid leukaemia	DIS0BM1I	2A60	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04778397) Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2). U.S. National Institutes of Health.